The U.S. Food and Drug Administration has told Zyn that it can market its nicotine pouches as a safer alternative to cigarettes, according to a report by STAT News. The decision is a significant regulatory milestone for the smokeless nicotine product, which has grown rapidly in popularity, particularly among young adults.
Zyn pouches are small white packets that users place between the lip and gum. They deliver nicotine without smoke, vapor, or tobacco leaf. The product is made by Swedish Match, a subsidiary of Philip Morris International. Zyn has become one of the best-selling nicotine pouch brands in the United States.
The FDA's authorization allows the company to make what regulators call a modified risk claim. That means Zyn can now tell consumers, in its marketing and on its packaging, that its pouches present less risk than cigarettes. The agency reached that conclusion after reviewing scientific evidence about what happens when people switch from smoking cigarettes to using nicotine pouches instead.
The ruling does not mean Zyn is safe. Nicotine itself is addictive and carries health risks. The FDA's determination is based on a comparison to cigarettes specifically. Cigarettes produce tar and thousands of toxic chemicals through combustion, many of which are directly linked to lung cancer, heart disease, and other serious illnesses. Because Zyn involves no combustion or tobacco leaf, its chemical profile is substantially different.
Public health researchers have debated for years how to think about reduced-harm nicotine products. Some argue that products like nicotine pouches, e-cigarettes, and heated tobacco devices serve a legitimate harm-reduction purpose for adult smokers who cannot or will not quit nicotine entirely. Others warn that marketing these products as safer could encourage people who never smoked to start using them, particularly teenagers and young adults.
Zyn has already drawn scrutiny from lawmakers and health advocates over its popularity with younger users. Senator Chuck Schumer called for a federal investigation into the product in 2024, raising concerns about its marketing and its appeal to people under 21. The FDA's new authorization is likely to renew that debate.
The agency requires companies seeking modified risk authorization to demonstrate that their product will benefit public health as a whole, not just individual users who switch from cigarettes. That standard is meant to ensure regulators weigh any potential benefit to current smokers against the risk of attracting new users who would otherwise not be consuming nicotine.
The Zyn decision sets a precedent that other nicotine pouch manufacturers may now try to follow. Several competing products have entered the U.S. market in recent years, and the regulatory pathway that Zyn has now cleared could reshape how the broader smokeless nicotine category is marketed going forward.
